Spanios

Executive Summary

Spanios is a biotechnology company founded in 2021 and headquartered in Cambridge, USA, focused on transforming cancer drug development through its proprietary 3D tumor organoid platform, COMPASS. The platform generates Patient Derived Tumoroids (PDTs) that preserve an intact tumor microenvironment and functional immune components, offering a more physiologically relevant preclinical model compared to traditional 2D cultures or animal models. By enabling the testing of next-generation therapeutics in a human-relevant context, Spanios aims to accelerate the validation of novel cancer treatments across solid tumor indications, potentially increasing the success rate of drugs entering clinical trials and reducing development timelines.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with pharmaceutical or large biotech company for platform validation and service agreement60% success
• Q2 2027Presentation of key preclinical validation data at major oncology conference (e.g., AACR, ASCO)70% success
• Q1 2027Completion of Series A financing round to scale platform and expand indications50% success